Business · 17/12/1998Updated: 10/17/2026 · 1 min read
FDA Withdraws Approval of Estrogen-Containing Drugs for Postpartum Breast Engorgement
Summary
The FDA is withdrawing approval of estrogen-containing drugs for postpartum breast engorgement due to concerns over their safety for this specific use.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →